Clinical trial of butylphthalide injection in the treatment of patients with progressive cerebral infarction
10.13699/j.cnki.1001-6821.2018.05.008
- VernacularTitle:丁苯酞注射液治疗进展性脑梗死的临床研究
- Author:
Lin-Ting XIAO
1
;
Hui ZHOU
;
Cong CHEN
Author Information
1. 三亚市人民医院神经内科
- Keywords:
butylphthalide injection;
clopidogrel tablet;
progressive cerebral infarction;
neurological function;
fibrinogen
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(5):514-517
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of butylphthalide injection on neurological function and plasma fibrinogenin in patients with progressive cerebral infarction.Methods Seventy-eight patients with progressive cerebral infarction were randomly divided into control group (n =39) and treatment group (n =39).Control group was orally given clopidogrel 300 mg + aspirin 100 mg on first day,qd,and orally given clopidogrel 75 mg + aspirin 100 mg on 2-14 d,qd.On the basis of control group,treatment group was treated with butylphthalide and sodium chloride injection 100 mL,bid,interval time ≥ 6 h,intravenous drip.All the patients were treated for 2 weeks.The clinical effect,the levels of plasma fibrinogen (Fib),D-dimer (D-D),platelet count (PC),mean platelet volume (MPV),endothelin-1 (ET-1),nitric oxide (NO),vascular endothelial growth factor (VEGF),the National institute of health stroke scale (NIHSS),Barthel index(BI) score,and the incidence of adverse drug reactions in two grousp were compared.Results After treatment,the improved rates in control group and treatment group were 74.36％ (29 cases/39 cases),92.31％ (36 cases/39cases),with significant difference (P ＜0.05).After treatment,the levels of Fib in treatment group and control group were (2.75 ± 1.04) and (3.58 ± 1.20) g · L-1,the D-D were (0.71 ± 0.34) and (0.98 ± 0.39) mg · L-1,the PC were (157.42 ± 10.28) × 109/L and (165.35 ± 11.47) × 109/L,the MPV were (10.41 ± 1.21)and(11.98 ±1.35)fL,the ET-1 were(61.24 ±9.84) and(70.26 ± 10.07)ng · mL-1,the VEGF were(143.69 ± 25.87) and (210.03 ± 28.68) ng · mL-1,the NO were (65.34 ± 13.27) and (53.26 ± 12.45)U · mL-1,the NIHSS were 4.19 ±2.05 and 6.41 ±2.26,the BI scores were 46.15 ±5.97 and 40.82 ±5.34,all with significant difference (all P ＜ 0.05).The adverse drug reactions were nausea,vomiting,rash and head discomfort in treatment group,with the incidence of 15.38％.The adverse drug reactions were nausea,vomiting and fever in control group,with the incidence of 12.82％.There was no difference in the incidence of adverse drug reactions between the two groups (P ＞ 0.05).Conclusion The clinical effect of butylphthalide is great in the treatment of progressive cerebral infarction patients,and can improve the nerve defect and vascular endothelial function,reduce the content of fibrinogen in plasma with high safety.
